Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors

References

• Alexandre E, Baze A, Parmentier C, et al. (2012). Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers. Xenobiotica 42:968
   PubMed Web of Science ®Google Scholar
• Alexandre E, Viollon-Abadie C, David P, et al. (2002). Cryopreservation of adult human hepatocytes obtained from resected liver biopsies. Cryobiology 44:103–13
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Baciewicz FA, Jr. (1993). Ketoconazole and fluconazole drug interactions. Arch Intern Med 153:1970–6
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug--drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
   PubMed Web of Science ®Google Scholar
• Blanchard N, Alexandre E, Abadie C, et al. (2005). Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35:1–15
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1999). Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 2:47–52
   PubMed Web of Science ®Google Scholar
• Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293–301
   PubMed Web of Science ®Google Scholar
• Brown HS, Ito K, Galetin A, Houston JB. (2005). Prediction of in vivo drug--drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508–18
   PubMed Web of Science ®Google Scholar
• Chaikin P, Gillen MS, Malik M, et al. (2005). Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol 59:346–54
   PubMed Web of Science ®Google Scholar
• Chao P, Uss AS, Cheng KC. (2010). Use of intrinsic clearance for prediction of human hepatic clearance. Expert Opin Drug Metab Toxicol 6:189–98
   PubMed Web of Science ®Google Scholar
• Chen M, Nafziger AN, Bertino JS, Jr. (2006). Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos 34:2079–82
   PubMed Web of Science ®Google Scholar
• Chiba M, Ishii Y, Sugiyama Y. (2009). Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262–76
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Yeo KR, Howgate EM, et al. (2011). Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:623–38
   PubMed Web of Science ®Google Scholar
• Emoto C, Murase S, Iwasaki K. (2006). Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 36:671–83
   PubMed Web of Science ®Google Scholar
• Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2010). Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11:678–85
   PubMed Web of Science ®Google Scholar
• Engels FK, Mathot RA, Loos WJ, et al. (2006). Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Therapy 5:833–9
   PubMed Web of Science ®Google Scholar
• FDA. (2006). Guidance for industry. Drug interaction studies – study design, data analysis, and implications for dosing and labeling (Draft Guidance). U.S. Department of Health and Human Services, Food and Drug Administration
   Google Scholar
• Floby E, Johansson J, Hoogstraate J, et al. (2009). Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica 39:656–62
   PubMed Web of Science ®Google Scholar
• Floren LC, Bekersky I, Benet LZ, et al. (1997). Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41–9
   PubMed Web of Science ®Google Scholar
• Galetin A, Burt H, Gibbons L, Houston JB. (2006). Prediction of time-dependent CYP3A4 drug--drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166–75
   PubMed Web of Science ®Google Scholar
• Gibbs MA, Hosea NA. (2003). Factors affecting the clinical development of cytochrome p450 3A substrates. Clin Pharmacokinet 42:969–84
   PubMed Web of Science ®Google Scholar
• Glynn AM, Slaughter RL, Brass C, et al. (1986). Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 39:654–9
   PubMed Web of Science ®Google Scholar
• Goodman A, Hardman JG, Limbird LE, et al. (1996). Goodman and Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill
   Google Scholar
• Hallifax D, Galetin A, Houston JB. (2008). Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 38:353–67
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Gomez-Lechon MJ, Houston JB, et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234
   PubMed Web of Science ®Google Scholar
• Howgate EM, Rowland Yeo K, Proctor NJ, et al. (2006). Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 36:473–97
   PubMed Web of Science ®Google Scholar
• Ito K, Suzuki H, Horie T, Sugiyama Y. (2005). Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22:1559–77
   PubMed Web of Science ®Google Scholar
• Jacobson L, Middleton B, Holmgren J, et al. (2007). An optimized automated assay for determination of metabolic stability using hepatocytes: assay validation, variance component analysis, and in vivo relevance. Assay Drug Dev Technol 5:403–15
   PubMedGoogle Scholar
• Jouin D, Blanchard N, Alexandre E, et al. (2006). Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. Eur J Pharm Biopharm 63:347–55
   PubMed Web of Science ®Google Scholar
• Kafert-Kasting S, Alexandrova K, Barthold M, et al. (2006). Enzyme induction in cryopreserved human hepatocyte cultures. Toxicology 220:117–25
   PubMed Web of Science ®Google Scholar
• Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ. (1987). Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. Clin Pharmacol Ther 42:465–70
   PubMedGoogle Scholar
• Kato M, Chiba K, Ito T, et al. (2010). Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. Drug Metab Pharmacokinet 25:367–78
   PubMed Web of Science ®Google Scholar
• Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. (1999). CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–27
   PubMed Web of Science ®Google Scholar
• Lam YW, Alfaro CL, Ereshefsky L, Miller M. (2003). Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274–82
   PubMed Web of Science ®Google Scholar
• Lecluyse EL, Alexandre E. (2010). Isolation and culture of primary hepatocytes from resected human liver tissue. Methods Mol Biol 640:57–82
   PubMedGoogle Scholar
• Lecluyse EL, Alexandre E, Hamilton GA, et al. (2005). Isolation and culture of primary human hepatocytes. Methods Mol Biol 290:207–29
   PubMedGoogle Scholar
• Li AP. (2007). Human hepatocytes: Isolation, cryopreservation and applications in drug development. Chem-Biol Interact 168:16–29
   PubMed Web of Science ®Google Scholar
• Lin YS, Lockwood GF, Graham MA, et al. (2001). In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781–91
   PubMedGoogle Scholar
• Lu C, Berg C, Prakash SR, et al. (2008a). Prediction of pharmacokinetic drug--drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro--in vivo correlation with fluconazole. Drug Metab Dispos 36:1261–6
   PubMed Web of Science ®Google Scholar
• Lu C, Hatsis P, Berg C, et al. (2008b). Prediction of pharmacokinetic drug--drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro--in vivo correlation with ketoconazole. Drug Metab Dispos 36:1255–60
   PubMed Web of Science ®Google Scholar
• Lu C, Li P, Gallegos R, et al. (2006). Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600–5
   PubMed Web of Science ®Google Scholar
• Lu C, Miwa GT, Prakash SR, et al. (2007). A novel model for the prediction of drug--drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 35:79–85
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky M, Harrelson J, et al. (2012). Predictions of CYP-mediated drug--drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40:706--16
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. (2011). Prediction of CYP3A-mediated drug--drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591–602
   PubMed Web of Science ®Google Scholar
• Marfo K, Altshuler J, Lu A. (2010). Tacrolimus pharmacokinetic and pharmacogenomic differences between adults and pediatric solid organ transplant recipients. Pharmaceutics 2:291–9
   PubMedGoogle Scholar
• McGinnity DF, Berry AJ, Kenny JR, et al. (2006). Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291–300
   PubMed Web of Science ®Google Scholar
• Obach RS. (1996). The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro–in vivo correlations. Drug Metab Dispos 24:1047–9
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–405
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 316:336–48
   PubMed Web of Science ®Google Scholar
• Paixao P, Gouveia LF, Morais JA. (2010). Prediction of the in vitro intrinsic clearance determined in suspensions of human hepatocytes by using artificial neural networks. Eur J Pharm Sci 39:310–21
   PubMed Web of Science ®Google Scholar
• Rendic S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448
   PubMed Web of Science ®Google Scholar
• Richert L, Alexandre E, Lloyd T, Orr S, Viollon-Abadie C, Patel R, Kingston S, Berry D, Dennison A, Heyd B, et al. (2004). Tissue collection, transport and isolation procedures required to optimize human hepatocyte isolation from waste liver surgical resections. a multilaboratory study. Liver Int 24:371–8
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304–11
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. (2008). Drug–drug interactions. New York: Informa Healthcare
   Google Scholar
• Schiano TD, Bellary SV, Cassidy MJ, et al. (1996). Subfulminant liver failure and severe hepatotoxicity caused by loratadine use. Ann Intern Med 125:738–40
   PubMedGoogle Scholar
• Shou M, Hayashi M, Pan Y, et al. (2008). Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36:2355–70
   PubMed Web of Science ®Google Scholar
• Simon S, Blanchard N, Alexandre E, et al. (2009). The comparison of fresh and cryopreserved human hepatocytes for the prediction of metabolic clearance in humans, an update. The Medicon Valley – Hepatocyte User Forum (MV-HUF)
   Google Scholar
• Soars MG, Grime K, Sproston JL, et al. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–65
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK, Jones C, Ferguson D, et al. (2012). Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841–53
   PubMed Web of Science ®Google Scholar
• Stephenne X, Najimi M, Sokal EM. (2010). Hepatocyte cryopreservation: is it time to change the strategy? World J Gastroenterol 16:1–14
   PubMed Web of Science ®Google Scholar
• Stringer R, Nicklin PL, Houston JB. (2008). Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38:1313–29
   PubMed Web of Science ®Google Scholar
• Tham LS, Lee HS, Wang L, et al. (2006). Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. Ther Drug Monit 28:255–61
   PubMedGoogle Scholar
• Tornio A, Niemi M, Neuvonen PJ, Backman JT. (2012). Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 33:312–22
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential towards a consensus. Br J Clin Pharmacol 52:107–17
   PubMed Web of Science ®Google Scholar
• Tuteja S, Alloway RR, Johnson JA, Gaber AO. (2001). The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71:1303–7
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Schmider J, Harmatz JS, et al. (2001). Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 41:1043–54
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Hyland R, et al. (2012). Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:1686–97
   PubMed Web of Science ®Google Scholar
• Wan H, Bold P, Larsson LO, et al. (2010). Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model. Curr Drug Metab 11:583–94
   PubMedGoogle Scholar
• Williams JA, Hyland R, Jones BC, et al. (2004). Drug–drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–8
   PubMed Web of Science ®Google Scholar
• Xu L, Chen Y, Pan Y, et al. (2009). Prediction of human drug–drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330–9
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, et al. (2007). Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 35:501–2
   PubMed Web of Science ®Google Scholar
• Yumibe N, Huie K, Chen KJ, et al. (1996). Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 51:165–72
   PubMed Web of Science ®Google Scholar
• Zahir H, McCaughan G, Gleeson M, et al. (2004). Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 57:298–309
   PubMed Web of Science ®Google Scholar
• Zahir H, Nand RA, Brown KF, et al. (2001). Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 46:27–35
   PubMedGoogle Scholar
• Zanelli U, Caradonna NP, Hallifax D, et al. (2012). Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs. Drug Metab Dispos 40:104–10
   PubMed Web of Science ®Google Scholar
• Zhang H, Davis CD, Sinz MW, Rodrigues AD. (2007). Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667–87
   PubMed Web of Science ®Google Scholar
• Zhang J, Kuehl P, Green ED, et al. (2001). The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555–72
   PubMedGoogle Scholar
• Zhao P, Kunze KL, Lee CA. (2005). Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853–61
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310–22
   PubMed Web of Science ®Google Scholar
• Zhu B, Liu ZQ, Chen GL, et al. (2003). The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 55:264–9
   PubMed Web of Science ®Google Scholar